Search This Blog

Monday, November 11, 2024

Select Medical Special Stock Distribution to Spin-Off Concentra

 Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced that its Board of Directors has approved a special stock distribution (the "Distribution") to Select Medical's stockholders of the 104,093,503 shares of common stock of Concentra Group Holdings Parent, Inc. ("Concentra") (NYSE: CON) owned by Select Medical Corporation ("SMC"), a wholly owned subsidiary of Select Medical, representing approximately 81.7% of the outstanding shares of Concentra's common stock.

The Distribution by Select Medical of the special stock distribution will be made on November 25, 2024 (the "Distribution Date") to all of Select Medical's stockholders on the record date of November 18, 2024 (the "Record Date"). The Distribution will consist of a pro rata common stock distribution to each of Select Medical's stockholders on the Record Date. As of November 5, 2024, Select Medical had approximately 128,992,850 shares of its common stock, par value $0.001 per share, outstanding. Based on such number, Select Medical estimates that Select Medical's stockholders will receive approximately 0.806971 shares of Concentra's common stock for every share of Select Medical's common stock held as of the close of business on the Record Date. The final distribution ratio will be determined based on the number of shares of Select Medical's common stock outstanding on the Record Date.

https://www.prnewswire.com/news-releases/select-medical-holdings-corporation-announces-declaration-of-a-special-stock-distribution-to-spin-off-concentra-302297993.html

CERo Preclinical Data Shows CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.  The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference held in Houston November 6-10, 2024.

https://www.globenewswire.com/news-release/2024/11/11/2978290/0/en/CERo-Therapeutics-Inc-Presents-Preclinical-Data-Demonstrating-CER-1236-Killing-Ovarian-Cancer-Cell-Lines-Without-Toxicity.html

RadNet Soars 20.3% Pre-Market on AI-Driven Growth and Upgraded Guidance

 RadNet (NASDAQ:RDNT) is on a roll, smashing revenue records in Q3 2024 with a 14.7% year-over-year jump to $461.1 million. Its share price jumped by more than 20% in the pre-market trading today. The Digital Health segment is the real showstopper, with revenue soaring 34.3%, thanks to a 75.8% spike in AI-powered tools like its Enhanced Breast Cancer Detection (EBCD) program. While adjusted EPS of $0.18 missed analyst estimates by $0.06, the company delivered a stellar 27.2% boost in adjusted EBITDA, showcasing resilience against rising costs and strong demand for advanced imaging.

CEO Dr. Howard Berger isn't just celebrating; he's doubling down on growth. The launch of RadNet's DeepHealth OS platform at December's RSNA conference is set to put the company's AI innovation in the spotlight. Meanwhile, procedural volumes surged 9%, and same-center volumes climbed 5.5%, prompting RadNet to raise its full-year guidance for revenue, adjusted EBITDA, and free cash flow. The revised revenue target now sits between $1.71 billion and $1.76 billion, cementing the company's upward trajectory and signaling confidence in its strategic investments.

And the balance sheet? Rock solid. With $748.9 million in cash and a record-low leverage ratio below 1.0x, RadNet is locking in its financial strength while aggressively expanding. Investors should keep their eyes on the DeepHealth OS debut, which could unlock a new growth chapter as AI-powered healthcare transforms the industry. RadNet isn't just keeping up with demandit's defining the future of diagnostic imaging.

GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™

  • Collaboration will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to further the innovation, commercialization, and adoption of AI in imaging.
  • Together, GE HealthCare and RadNet’s DeepHealth aim to create SmartTechnology™ solutions that harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain to improve speed, clinical accuracy, operational efficiency, and elevate patient care.
  • To demonstrate the promise of this strategic relationship, the collaboration will first work to bring together DeepHealth’s AI-powered SmartMammo™ 1 solution with GE HealthCare’s patient-centric Senographe Pristina™ mammography system to enhance the way women receive breast care.
  • The two companies intend to explore additional areas of collaboration to further expand the access and impact of AI-based workflows in other imaging modalities.

FDA Removes Hold on Novavax COVID-19-Influenza Combo, Stand-alone Influenza Phase 3

 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.

"We thank the FDA for their partnership and thorough review of the additional information provided as part of our response package," said Robert Walker, MD, Chief Medical Officer, Novavax. "The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine. We plan to start our Phase 3 trial as soon as possible."

https://www.prnewswire.com/news-releases/us-fda-removes-clinical-hold-on-novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-phase-3-trial-302301171.html

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails

 Bristol Myers Squibb (BMY) stock rocketed Monday after AbbVie's (ABBV) experimental schizophrenia treatment failed in a pair of midstage studies.

The news bolsters Bristol Myers' new schizophrenia treatment, Cobenfy.

Bristol spent $14 billion earlier this year to acquire Karuna Therapeutics for Cobenfy, the drug formerly called KarXT. Cobenfy gained Food and Drug Administration approval in September. It's the first drug in its class. AbbVie was looking to rival Cobenfy with its drug, emraclidine.

But emraclidine failed to make a difference in two Phase 2 studies. AbbVie tested emraclidine in patients with schizophrenia who experienced an acute exacerbation of psychotic symptoms. After six weeks, the patients who received emraclidine didn't show a significant improvement in symptoms compared to the placebo recipients.

https://www.investors.com/news/technology/bristol-myers-squibb-stock-abbvie-stock-schizophrenia-treatment/

Sunday, November 10, 2024

New guidelines for preventing stroke, the nation's 4th biggest killer

 The majority of strokes could be prevented, according to new guidelines aimed at helping people and their doctors do just that.

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention, and more than half a million Americans have a stroke every year. But up to 80% of strokes may be preventable with better nutrition, exercise and identification of risk factors.

The first new guidelines on  in 10 years from the American Stroke Association, a division of the American Heart Association, include recommendations for people and doctors that reflect a better understanding of who gets strokes and why, along with  that can help reduce risk.

The good news is that the best way to reduce your risk for stroke is also the best way to reduce your risk for a whole host of health problems—eat a , move your body and don't smoke. The bad news is that it's not always so easy to sustain.

Dr. Sean Duke, a stroke doctor at the University of Mississippi Medical Center, blames the forces in society that keep people sedentary and eating poorly, like cell phones and cheap, unhealthy food. "Our world is stacked against us," he said.

Here's what to know about stroke and the new guidelines:

What is a stroke?

A stroke happens when  to part of the brain is blocked or if a blood vessel in the brain bursts. That deprives the brain of oxygen which can cause  that can lead to difficulty thinking, talking and walking, or even death.

Eating healthy can reduce your risk for stroke

Eating healthy can help control several factors that increase your risk for stroke, including high cholesterol, high blood sugar, and obesity, according to the heart association.

The group recommends foods in the so-called Mediterranean diet such as fruits, vegetables, whole grains and olive oil, which can help keep cholesterol levels down. It suggests limiting red meat and other sources of saturated fat. Instead, get your protein from beans, nuts, poultry, fish and seafood.

Limit highly processed foods and foods and drinks with a lot of added sugar. This can also reduce your calorie intake, which helps keep weight in check.

Moving your body can help prevent strokes

Getting up and walking around for at least 10 minutes a day can "drastically" reduce your risk, said Dr. Cheryl Bushnell, a neurologist at Wake Forest University School of Medicine who was part of the group that came up with the new guidelines. Among the many benefits: Regular exercise can help reduce blood pressure, a major risk factor for stroke.

Of course, more is better: The heart association recommends at least 150 minutes of moderate aerobic or 75 minutes of vigorous activity—or some combination—per week. How you do it doesn't matter so much, experts said, Go to the gym, take a walk or run in your neighborhood or use treadmills or stepper machines at home.

New tools to reduce obesity, a risk factor

Diet and exercise can help control weight, another important risk factor for strokes. But a new class of drugs that can drastically reduce weight have been approved by regulators, providing new tools to reduce stroke risk since guidelines were last updated.

The guidelines now recommend that doctors consider prescribing these drugs, including those sold under the brand names Ozempic, Wegovy, Mounjaro and Zepbound, to people with obesity or diabetes.

But while those drugs can help, people still need to eat well and get exercise, cautions Dr. Fadi Nahab, a stroke expert at Emory University Hospital.

People who might be at higher risk for stroke

The new guidelines for the first time recommend doctors screen patients for other factors that could increase stroke risk, including sex and gender and non-medical factors such as economic stability, access to health care, discrimination and racism. For example, the risk for having a first stroke is nearly twice as high for Black adults in the U.S. as it is for white adults, according to the CDC.

"If somebody doesn't have insurance or they can't get to a doctor's office because of transportation issues or they can't get off work to get health care ... these are all things that can impact the ability to prevent stroke," Bushnell said.

Doctors may be able to point to resources for low-cost health care or food, and can give ideas about how to be active without breaking the bank for a gym membership.

The guidelines also now recommend doctors should screen for conditions that could increase a woman's risk for stroke, such as high blood pressure during pregnancy or early menopause.

How do I know if I'm having a stroke and what do I do?

Three of the most common stroke symptoms include face weakness, arm weakness and difficulty speaking. And time is important, because brain damage can happen quickly and damage can be limited if a stroke is treated quickly. Stroke experts have coined an acronym to help you remember: FAST. F for face, A for arm, S for speech, and T for time. If you think you or a loved one could be having a , call 911 right away.

https://medicalxpress.com/news/2024-11-guidelines-nation-4th-biggest-killer.html

'1 in 5 people could have long COVID'

 More than 1 in 5 Americans likely suffer from long COVID, a new AI-assisted review has found.

The analysis suggests that nearly 23% of U.S. adults experience the symptoms of long COVID, according to results published Nov. 8 in the journal Med.

That's much higher than the 7% prevalence of long COVID that's been suggested by other studies, researchers said.

"Questions about the true burden of long COVID -- questions that have thus far remained elusive -- now seem more within reach," said senior researcher Hossein Estiri, head of AI research at Mass General Brigham in Boston.

For the study, researchers developed an AI tool that can sift through mounds of electronic health records looking for the frequently subtle symptoms related to long COVID.

These symptoms can occur in a wide range of body systems, and include fatigue, chronic cough,  and "brain fog." They typically develop weeks or months after a person shakes off their initial COVID-19 infection.

"Our AI tool could turn a foggy diagnostic process into something sharp and focused, giving clinicians the power to make sense of a challenging condition," Estiri said in a Mass General news release.

The AI specifically looks for symptoms that can't be explained by a person's medical history, have persisted for two months or longer and occur following a COVID infection, researchers said.

For example, the AI can detect if shortness of breath might be explained by pre-existing  or asthma, rather than long COVID.

"Physicians are often faced with having to wade through a tangled web of symptoms and medical histories, unsure of which threads to pull, while balancing busy caseloads. Having a tool powered by AI that can methodically do it for them could be a game-changer," said lead researcher Dr. Alaleh Azhir, an internal medicine resident at Brigham and Women's.

Based on these parameters, the AI estimated that nearly 23% of Americans likely have long COVID, a figure that researchers argue aligns more closely with national trends.

The researchers plan to release the AI publicly on open access, so doctors and health care systems can employ and test it.

More information: Precision Phenotyping for Curating Research Cohorts of Patients with Unexplained Post-Acute Sequelae of COVID-19, Med (2024). DOI: 10.1016/j.medj.2024.10.009www.cell.com/med/fulltext/S2666-6340(24)00407-0


https://medicalxpress.com/news/2024-11-people-covid.html